Prevnar 13

BIOLOGICAL16 trials

Sponsors

GlaxoSmithKline, Nuron Biotech Inc., St. Antonius Hospital, Lakehead University, Jiangsu Province Centers for Disease Control and Prevention

Conditions

Bacterial InfectionsChronic Kidney DiseasesExtraintestinal Pathogenic Escherichia Coli PreventionImmune ResponseInfectious DiseaseLymphomaMeaslesMeasles-Mumps-Rubella Vaccine

Early Phase 1

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

CompletedNCT02851056

H. Lee Moffitt Cancer Center and Research InstituteMultiple Myeloma

Start: 2016-09-27End: 2018-08-09Updated: 2022-11-14

Phase 1

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

CompletedNCT03642847

PfizerPneumococcal Infections

Start: 2018-08-29End: 2019-03-29Updated: 2019-06-12

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

CompletedNCT03819049

Janssen Research & Development, LLCExtraintestinal Pathogenic Escherichia Coli Prevention

Start: 2019-06-06End: 2024-12-18Updated: 2025-05-25

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

CompletedNCT06183216

Sinovac Research and Development Co., Ltd.Pneumococcal Infectious Disease

Start: 2024-01-04End: 2025-03-26Updated: 2026-01-28

Phase 2

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

Nuron Biotech Inc.Infectious Disease

Start: 2013-03-31End: 2014-04-30Target: 220Updated: 2013-09-23

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

CompletedNCT03313037

PfizerPneumococcal Infections

Start: 2017-10-10End: 2018-12-10Updated: 2019-12-26

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

TerminatedNCT03550313

PfizerPneumococcal Infections

Start: 2018-06-01End: 2020-11-05Updated: 2021-11-30

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

CompletedNCT05412030

GlaxoSmithKlinePneumococcal Infections, Pneumonia, Bacterial, Pneumonia, Pneumococcal

Start: 2022-06-16End: 2025-09-18Updated: 2025-10-21

Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

CompletedNCT01681992

GlaxoSmithKlineMeasles, Measles-Mumps-Rubella Vaccine, Mumps +1

Start: 2012-10-10End: 2015-08-18Updated: 2021-01-07

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

CompletedNCT01702428

GlaxoSmithKlineMeasles, Mumps, Rubella

Start: 2012-11-09End: 2015-04-16Updated: 2019-11-25

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

CompletedNCT02184572

GlaxoSmithKlineMeasles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine

Start: 2014-08-25End: 2015-12-22Updated: 2021-01-07

A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

CompletedNCT02494999

Jiangsu Province Centers for Disease Control and PreventionPneumonia

Start: 2016-06-30End: 2019-10-31Updated: 2020-05-13

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

RecruitingNCT07017777

CanSino Biologics Inc.Bacterial Infections, Pneumococcal Infections, Streptococcal Infections

Start: 2025-11-14End: 2028-05-15Target: 600Updated: 2026-02-27

Phase 4

Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status

CompletedNCT02141009

St. Antonius HospitalImmune Response, Pneumonia, Streptococcus Pneumoniae

Start: 2014-04-30End: 2014-12-31Updated: 2014-12-23

The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13

CompletedNCT02370069

Lakehead UniversityChronic Kidney Diseases

Start: 2015-06-30End: 2020-08-31Updated: 2021-09-09

Vaccine Responses in Patients With B Cell Malignancies

RecruitingNCT05170399

National Heart, Lung, and Blood Institute (NHLBI)Lymphoma

Start: 2022-09-14End: 2026-08-16Target: 500Updated: 2026-02-05

Related Papers

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI

npj Vaccines2024-06-1413 citations

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Clinical Cancer Research2023-09-2215 citations

Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study

Open Forum Infectious Diseases2023-08-0126 citations

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial

Human Vaccines & Immunotherapeutics2023-08-013 citations

120. Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study

Open Forum Infectious Diseases2022-12-012 citations

Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.

2022-06-211 citations

A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old.

2021-10-244 citations

A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

Human Vaccines & Immunotherapeutics2021-02-0515 citations

1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age

Open Forum Infectious Diseases2020-10-012 citations

16. A Randomized Phase 1 Study of a Novel Pneumococcal Conjugate Vaccine in Healthy Japanese Adults in the United States

Open Forum Infectious Diseases2020-10-01

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

Clinical Infectious Diseases2020-07-22156 citations

Advances in Dendritic Cell-Based Therapies for Hematologic Malignancies

Oncology Times2020-04-10

The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.

2019-11-124 citations

Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates

The Journal of Infectious Diseases2019-07-1012 citations

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

Journal of the Pediatric Infectious Diseases Society2019-02-2817 citations

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

Human Vaccines & Immunotherapeutics2018-08-1710 citations

Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.

2018-08-109 citations

Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.

2017-08-095 citations